Carlson Matthew, Wuertz Beverly, Lin Jizhen, Taylor Randy, Ondrey Frank
Department of Otolaryngology, University of Minnesota, MMC 396, 420 Delaware ST SE, Minneapolis, MN 55455, USA.
Int J Otolaryngol. 2009;2009:649615. doi: 10.1155/2009/649615. Epub 2010 Jan 5.
Objective. Epidermal growth factor receptor (EGFR) tyrosine kinase inhibition (TKI) is a promising treatment in upper aerodigestive malignancies. EGFR inhibitors might be more effective in patients whose tumors harbor specific EGFR mutations. The presence of specific EFGR mutations is predictive of over a 75% response rate to TKI therapies as compared to 10% in wild type cases of non-small cell lung cancer. Our objective was to examine whether these mutations might occur in upper aerodigestive cancers. Design. DNA was extracted from 20 head and neck squamous cell tumors and 4 squamous cell carcinoma cell lines and sequenced the receptor using published primer pairs. We then compared the results against published mutations. Results. No exon 19 or 21 mutations were found in any of the 20 tumors and 0 of 4 cell lines. Based on the tumor data we would predict that no greater than 8% of head and neck tumors (CI 97.5%) would be likely to harbor either of these mutations. Conclusions. Our findings are comparable to results recently published of Korean, Austrian, and Spanish patient populations and we conclude that exon 19 and 21 EGFR mutations are not more common in head and neck cancer than in nonsmall-cell carcinoma.
目的。表皮生长因子受体（EGFR）酪氨酸激酶抑制（TKI）是上呼吸消化道恶性肿瘤一种有前景的治疗方法。EGFR抑制剂可能对肿瘤存在特定EGFR突变的患者更有效。与非小细胞肺癌野生型病例10%的反应率相比，特定EGFR突变的存在预示着对TKI治疗的反应率超过75%。我们的目的是研究这些突变是否可能在上呼吸消化道癌症中出现。设计。从20例头颈部鳞状细胞瘤和4个鳞状癌细胞系中提取DNA，并使用已发表的引物对测定受体序列。然后我们将结果与已发表的突变进行比较。结果。在20个肿瘤和4个细胞系中均未发现19或21外显子突变。根据肿瘤数据，我们预测头颈部肿瘤中不超过8%（97.5%置信区间）可能存在这两种突变中的任何一种。结论。我们的发现与最近发表的韩国、奥地利和西班牙患者群体的结果相当，我们得出结论，EGFR 19和21外显子突变在头颈部癌中并不比在非小细胞癌中更常见。
